Categories
Recommendation
- https://us.pluvicto.com/PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)PLUVICTO. Every day without progression is a VICTORY. Now available before chemotherapy for PSMA+. PLUVICTO— ...
- U.S. Food and Drug Administrationhttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancerFDA approves Pluvicto for metastatic castration-resistant prostate ...Mar 23, 2022 ... The Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company)
- https://us.pluvicto.com/about-pluvicto/how-pluvicto-worksWhat Is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?Remember it in 3 steps ... PLUVICTO is designed to find and attack PSMA+ cells. PSMA is found on many prostate cancer cells and also some healthy cells. When ...
- U.S. Food and Drug Administrationhttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indicationFDA expands Pluvicto's metastatic castration-resistant prostate ...Mar 28, 2025 ... The Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation)
- https://www.pluvicto-hcp.com/PLUVICTO® | Lutetium Lu 177 Vipivotide Tetraxetan InjectionPLUVICTO: The first and only PSMA-targeted RLT now approved after only 1 ARPI. 1 See trial data. PLUVICTO targets PSMA, a biomarker overexpressed in more than ...
- https://en.wikipedia.org/wiki/Lu-PSMA-617Lu-PSMA-617 - WikipediaLu-PSMA-617, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen ...
- Novartishttps://www.novartis.com/news/media-releases/fda-approves-novartis-radioligand-therapy-pluvicto-earlier-use-chemotherapy-psma-positive-metastatic-castration-resistant-prostate-cancerFDA approves Novartis radioligand therapy Pluvicto® for earlier use ...Mar 28, 2025 ... The US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for patients with prostate-specific membrane antigen (PSMA) ...
- https://www.pluvicto-hcp.com/psma-positive-mcrpc/pluvicto-and-psmaPLUVICTO and mCRPC | PLUVICTO HCPPLUVICTO (plu-VICK-toh) describes a PSMA-targeted (P) lutetium-based (LU) radioligand therapy in PSMA+ mCRPC, where another option for patients is a victory.
- Medscapehttps://www.medscape.com/viewarticle/fda-approves-pluvicto-earlier-use-psma-positive-metastatic-2025a10007lnFDA Okays Pluvicto for Earlier Use in Prostate CancerMar 31, 2025 ... The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor pathway ...
- https://www.uchicagomedicine.org/cancer/types-treatments/prostate-cancer/treatment/lutetium-177-psma-therapy-for-prostate-cancerLutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto ...Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto) ... Lutetium-177 vipivotide tetraxetan PSMA therapy (Pluvicto) is a new theranostic medicine for advanced ...